Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry... Show more
In recent trading sessions, Colgate-Palmolive (CL) stock has shown renewed vigor, rebounding from earlier pressures in developed markets. The shares have climbed amid broader consumer staples resilience, supported by steady demand for core oral care and pet nutrition products. Trading within a 52-week range reflecting prior peaks and troughs, CL benefits from a defensive profile with low beta and consistent dividend yield around 2.3%. Analyst upgrades highlight improving momentum, positioning the stock for potential outperformance in a volatile environment as investors seek stability in everyday essentials.
Colgate-Palmolive's stock surged over 5% immediately following its Q4 and full-year 2025 earnings release on January 30, 2026, as the company delivered results that exceeded Wall Street expectations and unveiled optimistic guidance alongside a new strategic framework. Adjusted earnings per share reached $0.95, surpassing the consensus of $0.91, while net sales hit $5.23 billion, topping forecasts of $5.12 billion. Organic sales growth accelerated to 2.2%, outpacing projections of 1.4%, fueled by robust performance across all major categories—particularly oral care and pet nutrition—despite exiting private-label pet food lines.
This beat triggered a wave of analyst enthusiasm. On February 2, firms like BofA Securities, Piper Sandler, Evercore ISI, Morgan Stanley, Citigroup, and Wells Fargo raised price targets, with several lifting to $100 from prior levels around $86-$94. Goldman Sachs adjusted to $94, Jefferies to $91, and UBS reiterated Buy at $93. Consensus now clusters around $94-$95, implying modest upside from recent levels near $92. These moves reflect confidence in Colgate's pricing power, sequential gross margin stabilization, and rebound in Latin America after prior product reformulations.
Key drivers included emerging markets strength, where Colgate holds leading positions, offsetting softer North America volumes amid consumer uncertainty. Pet nutrition, bolstered by the Prime 100 acquisition performing ahead of plan, contributed significantly. Full-year highlights featured record $4.2 billion operating cash flow, low leverage, and gross margins holding firm despite raw material and tariff pressures. A GAAP net loss stemmed from non-cash skin health impairments, but base business metrics shone.
Earlier in the period, a January 21 dividend declaration of $0.52 per share reinforced its Dividend King status, supporting sentiment. The launch of the 2030 Strategic Growth and Productivity Program (SGPP) aims to enhance omnichannel presence, digital investments, and organizational efficiency, building on the completed 2025 strategy that added $5 billion in sales. These factors linked directly to price action, with shares gaining amid sector rotation toward defensives and validation of Colgate's resilience in essentials spending.
Colgate-Palmolive enters 2026 with guidance for 1-4% organic sales growth and low- to mid-single-digit EPS expansion, framing a conservative yet achievable path amid volatile categories. Favorable FX tailwinds, especially early in the year, could bolster the higher end if consumer staples demand stabilizes. Investors should track emerging markets execution, where Colgate's oral care dominance and pet nutrition gains via Hill's and Prime 100 offer tailwinds, against North American softness in personal care.
Progress on the 2030 SGPP will be pivotal, focusing on productivity to fund innovation in premiumization, digital channels, and omnichannel expansion. Margin trajectory hinges on raw material costs, tariffs, and pricing discipline, with recent sequential improvements signaling potential. Competitive positioning in pet nutrition amid rising adoption, alongside regulatory shifts in key regions, merits attention. Broader macroeconomic pressures like inflation and geopolitics could pressure volumes, but Colgate's strong cash generation—evidenced by 2025 records—supports reinvestment and returns. Balanced monitoring of these themes will gauge sustained momentum.
CL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on March 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CL as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CL moved below its 50-day moving average on March 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CL's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for CL moved above the 200-day moving average on February 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CL advanced for three days, in of 318 cases, the price rose further within the following month. The odds of a continued upward trend are .
CL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 271 cases where CL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CL's P/B Ratio (1250.000) is very high in comparison to the industry average of (23.898). P/E Ratio (33.779) is within average values for comparable stocks, (60.215). Projected Growth (PEG Ratio) (3.422) is also within normal values, averaging (2.583). Dividend Yield (0.023) settles around the average of (0.036) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (3.507).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of oral, personal, and household products
Industry HouseholdPersonalCare